接受直接抗病毒药物治疗丙型肝炎病毒感染的肝硬化患者发生新发或复发性肝细胞癌风险增加的相关因素
一项在意大利单中心开展的回顾性研究纳入565例接受直接抗病毒药物(DAA)治疗的丙型肝炎病毒(HCV)感染肝硬化患者,中位随访25个月。无HCC史者新发HCC的3年累积概率为6%(95%CI 4%-9%),男性、糖尿病、肝硬度值(LSM)和FIB-4评分与新发HCC独立相关;有HCC史者复发3年累积概率为43%(95%CI 20%-61%),糖尿病与复发独立相关。
要点
- 无HCC史患者DAA治疗后新发HCC的3年累积概率为6%(95%CI 4%-9%)。
- 男性(HR 6.17)、糖尿病(HR 2.52)、LSM(HR 1.03)和FIB-4评分(HR 1.08)与新发HCC独立相关。
- 有HCC史患者复发3年累积概率为43%(95%CI 20%-61%),糖尿病与复发独立相关(HR 4.12)。
核心结论
- 在大型单中心连续肝硬化并接受DAA治疗HCV感染的患者队列中,多数肝脏肿瘤在早期阶段被识别。
- 男性、糖尿病和非侵入性肝纤维化标志物可用于识别DAA治疗后HCC风险增加的患者。
研究设计与样本
- 回顾性研究,纳入意大利单中心2014年12月至2016年期间接受DAA治疗的565例肝硬化患者,中位年龄64岁(范围28-87岁),60%为男性,49%感染HCV基因1型,中位肝硬度值(LSM)19.1 kPa,87%为Child-Pugh-Turcotte A级。
- 肝硬化基于临床特征、组织学因素(METAVIR F4)或LSM >11.9 kPa定义。
- 治疗期间每4周评估一次(完整血液分析和HCV-RNA定量),治疗后第4、12和24周评估,此后每6个月评估一次;根据HCC病史每3-6个月进行超声或CT扫描监测HCC。
主要发现
- 中位随访25个月(范围3-39个月)期间,无HCC史的505例患者中28例发生新发HCC,3年估计累积概率为6%(95%CI 4%-9%)。
- 新发HCC患者中75%为单发肿瘤,其中82%为巴塞罗那肝癌分期0-A期;甲胎蛋白中位水平为6 ng/mL(范围1.0-9240 ng/mL)。
- 男性(HR 6.17;95%CI 1.44-26.47;P = .01)、糖尿病(HR 2.52;95%CI 1.08-5.87;P = .03)、LSM(HR 1.03;95%CI 1.01-1.06;P = .01)和FIB-4评分(HR 1.08;95%CI 1.01-1.14;P = .01)与新发HCC独立相关。
- 有HCC史的60例患者中20例发生HCC复发,3年累积复发概率为43%(95%CI 20%-61%);20例复发患者中11例为单发肿瘤,90%为Child-Pugh-Turcotte A级。
- 糖尿病与HCC复发独立相关(HR 4.12;95%CI 1.55-10.93;P = .004)。
临床怎么用
- 作者认为,男性、糖尿病和非侵入性肝纤维化标志物可用于识别DAA治疗后HCC风险增加的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with cirrhosis and hepatitis C virus (HCV) infection treated with direct-acting antivirals (DAAs) are still at risk for developing hepatocellular carcinoma (HCC). We aimed to identify features of de novo or recurrent HCCs in these patients, and factors associated with HCC development, in a large cohort of patients with cirrhosis who received treatment with DAAs. METHODS: In a retrospective study, we collected data from 565 patients with cirrhosis (median age, 64 years; range, 28-87 years; 60% male, 49% infected with HCV genotype 1; median liver stiffness measurement [LSM], 19.1 kPa; 87% Child-Pugh-Turcotte score A) treated with DAAs at a single center in Italy, from December 2014 through 2016. Cirrhosis was defined based on clinical features, histologic factors (METAVIR F4), or LSM >11.9 kPa. Patients were assessed (complete blood analysis and HCV-RNA quantification) every 4 weeks during treatment; at weeks 4, 12, and 24 afterward; and at 6-month intervals thereafter. HCC surveillance was performed by ultrasound or CT scans every 3-6 months, based on history of HCC. Non-invasive markers of fibrosis, such as ratio of aspartate aminotransferase to platelets, fibrosis-4 (FIB-4) score, and LSMs were assessed. RESULTS: During a median 25 months of follow up (range, 3-39 months), HCC developed in 28/505 patients without a history of HCC (de novo HCC); the 3-year estimated cumulative probability for HCC was 6% (95% CI, 4%-9%). Of patients with de novo HCC, 75% had a single tumor and 82% of these were Barcelona liver cancer stage 0-A; the median level of alpha-fetoprotein was 6 ng/mL (range, 1.0-9240 ng/mL). Male sex (hazard ratio [HR], 6.17; 95% CI, 1.44-26.47; P = .01), diabetes (HR, 2.52; 95% CI, 1.08-5.87; P = .03), LSM (HR, 1.03; 95% CI, 1.01-1.06; P = .01), and FIB-4 score (HR, 1.08; 95% CI, 1.01-1.14; P = .01) were independently associated with de novo HCC. HCC developed in 20/60 patients with a history of HCC (HCC recurrence); the 3-year cumulative probability for recurrence was 43% (95% CI, 20%-61%). In the 20 patients with HCC recurrence, 11 had a single tumor and 90% were Child-Pugh-Turcotte score A. Diabetes was independently associated with HCC recurrence (HR, 4.12; 95% CI, 1.55-10.93; P = .004). CONCLUSIONS: In a large, single-center cohort of consecutive patients with cirrhosis and who received DAA treatment for HCV infection, most liver tumors were identified at early stages. Male sex, diabetes, and non-invasive markers of liver fibrosis can be used to identify patients at increased risk for HCC following DAAs therapy.
引用
- Degasperi E, D'Ambrosio R, Iavarone M, et al. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Clin Gastroenterol Hepatol. 2018. PMID: 30613002. doi:10.1016/j.cgh.2018.10.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。